Skip to content

Sections
- Health
- Pharma
- Biotech
- Hospitals
- Politics
- In the Lab
- First Opinion
- Gut Check
- The Watchdogs
Topics
Multimedia
Popular
STAT Plus

Job Board
About Us

Newsletters
My Account
- Settings
- Log Out

Newsletters
My Account
- Settings
- Log Out

Drug Prices

Pharmalot

Lawmakers ask CMS for details on money-back deal for pricey Novartis CAR-T drug

By Ed Silverman

Adam's Take

Gilead Sciences boxed in by Novartis’ bargain-bin CAR-T price strategy

By Adam Feuerstein

advertisement

Pharmalot

Pharmalittle: Hikma makes big price hikes; controversy over Glaxo hepatitis B vaccine supplies

By Ed Silverman

advertisement

Pharmalot

Pharmalittle: Why EpiPen pricing is so strange; India may waive trials for some drugs

By Ed Silverman

Pharmalot

Pharmalittle: GSK looks to sell antibiotics unit; China wins big price cuts on drugs

By Ed Silverman

The Pharmalot View

The art of the deal? Why a money-back guarantee for drugs is a bad idea

By Ed Silverman

Biotech

Trump’s FDA may be lowering the standards for drug approvals. What’s the fallout?

By Adam Feuerstein

advertisement

Pharmalot

This bill would reinstate a controversial drug discount for some hospitals

By Ed Silverman

advertisement

Pharmalot

A Senate bill would require drug makers to justify price hikes

By Ed Silverman

Politics

Senate set to hear pitch on three ideas to bring down drug prices

By Erin Mershon

Pharmalot

Pfizer has raised prices on nearly 100 drugs by an average of 20 percent

By Ed Silverman

Pharma

Medicare patients don’t share in drug discounts given insurers and PBMs

By Sarah Jane Tribble — Kaiser Health News

Pharmalot

Bipartisan bill will be reintroduced to force pharma to justify price hikes

By Ed Silverman

Pharmalot

Lower FDA approval standards could have cost billions for a failed Alzheimer’s drug

By Ed Silverman

Pharmalot

Louisiana explores whether to override patents to fight hepatitis C drug costs

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Feds raid Perrigo in search of pricing information

By Ed Silverman

Pharmalot

Gilead loses a patent battle over Sovaldi in Brazil

By Ed Silverman

Pharmalot

Winners and losers: Who had a good week – and who didn’t

By Ed Silverman

Politics

PhRMA report pins consumers’ pain from high drug prices on health plans

By Dylan Scott

Pharmalot

Not just Colombia: Novartis has charged more for some drugs in Mexico, too

By Ed Silverman

Pharmalot

A new Senate bill would require PBMs to disclose some rebate info

By Ed Silverman

Pharmalot

Some states consider making it easier to dispense EpiPen alternatives

By Ed Silverman

Pharmalot

Still more lawmakers are probing Marathon over its DMD drug pricing

By Ed Silverman

Pharmalot

To import or not to import? Lawmakers push another bill to combat high drug prices

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Johnson & Johnson discloses drug prices to deflect criticism

By Ed Silverman

Pharmalot

Pharmalot, Pharmalittle: Some pharma execs exude confidence over US pricing

By Ed Silverman

Pharmalot

Chile’s congress votes to pursue compulsory licenses for medicines

By Ed Silverman

Pharmalot

An EpiPen rival will return, but with a questionable strategy

By Ed Silverman

Pharmalot

Alexion battles Canada over forfeiting sales for an ‘excessively’ priced drug

By Ed Silverman

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.

Industry

Sign up for our morning rounds newsletter

Reporting from the frontiers of health and medicine

About Us
Contact Us
The STAT Team
Work at STAT
Job Board
Advertise

Privacy
Comment Policy
Terms

© 2017 STAT

X